On the stock market since 2010, it operates in the world of health and science. It has 47,029 employees. Now — the numbers.
This is an established company with proven profits.
Revenue is spread across several lines; no single product carries the company.
The gap is $4.3T. In times of high interest rates, a gap like that can squeeze a company.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades below its recent peak — about 10% off the top. A pullback, not a collapse.
Over the last 12 months, company executives reported 53 buys and 7 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.63 per share each year — regular cash for whoever holds the stock.
The price action doesn’t yet back an upward turn. Council score: 0/10.
On our five-subject report card, TAK sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: TAK is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.